Why the study?
What are the pharmacokinetics, pharmacodynamics, efficacy, and safety characteristics of dihydropyridine calcium antagonists in treating arterial hypertension, ischemic heart disease, and chronic heart failure?
What are the pharmacokinetics, pharmacodynamics, efficacy, and safety characteristics of dihydropyridine calcium antagonists in treating arterial hypertension, ischemic heart disease, and chronic heart failure?
Answers are grounded in this paper and cite their sources.
This review summarizes the pharmacological properties and clinical applications of dihydropyridine calcium antagonists across various cardiovascular conditions.
This article contains information concerning the aspects of pharmacokinetics and pharmacodynamics of dihydropyridine calcium antagonists. The authors have discussed the evidence-based amlodipine treatment of arterial hypertension, ischemic heart disease and chronic heart failure. The authors present the comparison of the efficacy, safety and application characteristics of the different dihydropyridine calcium antagonists that can be used in specific clinical cases.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: